论文部分内容阅读
表皮生长因子受体(epidermal growth factor receptor,EGFR)-酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)被广泛应用于肿瘤的治疗,尤其是伴有EGFR基因突变的非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗,但EGFR-TKI耐药性的产生已成为制约其疗效的主要瓶颈。微小RNA(microRNAs,miRNAs)是一类非编码小分子RNA,在转录后水平调控基因的表达。近年来的研究发现,miRNAs在多个环节参与调节NSCLC对EGFR-TKI的敏感性,提示其可能在TKI耐药中扮演了重要角色,并有可能成为一种新的预测TKI敏感性的生物学标志物。因此,本文就有关NSCLC对EGFR-TKI的敏感性与miRNAs之间关系的最新研究进展进行综述。
Epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitor (TKI) is widely used in the treatment of tumors, especially non-small cell lung cancer with EGFR gene mutation (non- Small cell lung cancer, NSCLC), but the emergence of EGFR-TKI resistance has become the main bottleneck restricting its efficacy. MicroRNAs (miRNAs) are a class of non-coding small RNAs that regulate gene expression at the post-transcriptional level. Recent studies have found that miRNAs are involved in regulating the sensitivity of NSCLC to EGFR-TKI in multiple aspects, suggesting that miRNAs may play an important role in TKI resistance and may become a new biology for predicting TKI sensitivity landmark. Therefore, this review summarizes recent advances in the relationship between NSCLC sensitivity to EGFR-TKI and miRNAs.